Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis

Handan Canan,1 Selçuk Sizmaz,2 Rana Altan-Yaycioğlu,1 Çağla Saritürk,3 Gürsel Yilmaz41Department of Ophthalmology, Adana Teaching and Medical Research Center, Baskent University School of Medicine, 2Department of Ophthalmology, Çukurova University S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Canan H, Sızmaz S, Altan-Yaycıoğlu R, Sarıtürk C, Yılmaz G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	age-related macular degeneration (AMD) optical coherence tomography (OCT) ranibizumab visual acuity Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/982ea80c5aa34d329b31270e8bf84050
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:982ea80c5aa34d329b31270e8bf84050
record_format	dspace
spelling	oai:doaj.org-article:982ea80c5aa34d329b31270e8bf840502021-12-02T01:06:36ZVisual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis1178-1998https://doaj.org/article/982ea80c5aa34d329b31270e8bf840502014-01-01T00:00:00Zhttps://www.dovepress.com/visual-outcome-of-intravitreal-ranibizumab-for-exudative-age-related-m-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Handan Canan,1 Selçuk Sizmaz,2 Rana Altan-Yaycioğlu,1 Çağla Saritürk,3 Gürsel Yilmaz41Department of Ophthalmology, Adana Teaching and Medical Research Center, Baskent University School of Medicine, 2Department of Ophthalmology, Çukurova University School of Medicine, 3Department of Biostatistics, Adana Teaching and Medical Research Center, Baskent University School of Medicine, 4Department of Ophthalmology, Baskent University School of Medicine, Ankara, TurkeyPurpose: To describe 1-year clinical results of intravitreal ranibizumab treatment in patients with choroidal neovascularization secondary to exudative age-related macular degeneration (AMD) and to evaluate whether early treatment is a predictive value for prognosis of the disease.Materials and methods: Clinical records were retrospectively reviewed of 104 eyes that underwent intravitreal ranibizumab therapy for exudative AMD. Patients were divided into two groups according to their symptom duration: group 1, <1 month; and group 2, 1–3 months. After three monthly injections, patients were examined monthly, and subsequent injections were performed as needed.Results: There were 43 female (48.9%) and 45 males (51.1%). The follow-up time was 13.7±1.9 (12–19) months. The mean logarithm of minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly, from 0.45±0.639 at baseline to 0.08±0.267 at 12 months in group 1, and from 1.06±0.687 at baseline to 0.75±0.563 at 12 months in group 2. The increase in BCVA was statistically significant in group 1 (P=0.009). The mean central retinal thickness (CRT) decreased significantly, from 355.13±119.93 µm at baseline to 250.85±45.48 µm at 12 months in group 1, and from 371.88±91.047 µm at baseline to 268.61±53.51 µm at 12 months in group 2. The decrease in CRT was statistically significant in group 1 (P=0.001).Conclusion: Intravitreal ranibizumab therapy was effective in significantly increasing mean BVCA and reducing CRT. Shorter duration of AMD, as measured by the subjective duration of visual symptoms, is associated with better visual outcome after treatment.Keywords: age-related macular degeneration (AMD), optical coherence tomography (OCT), ranibizumab, visual acuityCanan HSızmaz SAltan-Yaycıoğlu RSarıtürk CYılmaz GDove Medical Pressarticleage-related macular degeneration (AMD)optical coherence tomography (OCT)ranibizumabvisual acuityGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 9, Pp 141-145 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	age-related macular degeneration (AMD) optical coherence tomography (OCT) ranibizumab visual acuity Geriatrics RC952-954.6
spellingShingle	age-related macular degeneration (AMD) optical coherence tomography (OCT) ranibizumab visual acuity Geriatrics RC952-954.6 Canan H Sızmaz S Altan-Yaycıoğlu R Sarıtürk C Yılmaz G Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
description	Handan Canan,1 Selçuk Sizmaz,2 Rana Altan-Yaycioğlu,1 Çağla Saritürk,3 Gürsel Yilmaz41Department of Ophthalmology, Adana Teaching and Medical Research Center, Baskent University School of Medicine, 2Department of Ophthalmology, Çukurova University School of Medicine, 3Department of Biostatistics, Adana Teaching and Medical Research Center, Baskent University School of Medicine, 4Department of Ophthalmology, Baskent University School of Medicine, Ankara, TurkeyPurpose: To describe 1-year clinical results of intravitreal ranibizumab treatment in patients with choroidal neovascularization secondary to exudative age-related macular degeneration (AMD) and to evaluate whether early treatment is a predictive value for prognosis of the disease.Materials and methods: Clinical records were retrospectively reviewed of 104 eyes that underwent intravitreal ranibizumab therapy for exudative AMD. Patients were divided into two groups according to their symptom duration: group 1, <1 month; and group 2, 1–3 months. After three monthly injections, patients were examined monthly, and subsequent injections were performed as needed.Results: There were 43 female (48.9%) and 45 males (51.1%). The follow-up time was 13.7±1.9 (12–19) months. The mean logarithm of minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly, from 0.45±0.639 at baseline to 0.08±0.267 at 12 months in group 1, and from 1.06±0.687 at baseline to 0.75±0.563 at 12 months in group 2. The increase in BCVA was statistically significant in group 1 (P=0.009). The mean central retinal thickness (CRT) decreased significantly, from 355.13±119.93 µm at baseline to 250.85±45.48 µm at 12 months in group 1, and from 371.88±91.047 µm at baseline to 268.61±53.51 µm at 12 months in group 2. The decrease in CRT was statistically significant in group 1 (P=0.001).Conclusion: Intravitreal ranibizumab therapy was effective in significantly increasing mean BVCA and reducing CRT. Shorter duration of AMD, as measured by the subjective duration of visual symptoms, is associated with better visual outcome after treatment.Keywords: age-related macular degeneration (AMD), optical coherence tomography (OCT), ranibizumab, visual acuity
format	article
author	Canan H Sızmaz S Altan-Yaycıoğlu R Sarıtürk C Yılmaz G
author_facet	Canan H Sızmaz S Altan-Yaycıoğlu R Sarıtürk C Yılmaz G
author_sort	Canan H
title	Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
title_short	Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
title_full	Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
title_fullStr	Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
title_full_unstemmed	Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
title_sort	visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/982ea80c5aa34d329b31270e8bf84050
work_keys_str_mv	AT cananh visualoutcomeofintravitrealranibizumabforexudativeagerelatedmaculardegenerationtimingandprognosis AT sızmazs visualoutcomeofintravitrealranibizumabforexudativeagerelatedmaculardegenerationtimingandprognosis AT altanyaycıoglur visualoutcomeofintravitrealranibizumabforexudativeagerelatedmaculardegenerationtimingandprognosis AT sarıtuumlrkc visualoutcomeofintravitrealranibizumabforexudativeagerelatedmaculardegenerationtimingandprognosis AT yılmazg visualoutcomeofintravitrealranibizumabforexudativeagerelatedmaculardegenerationtimingandprognosis
_version_	1718403334701842432

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis

Ejemplares similares